iCAD showcases its ProFound AI Suite at AHRA 2023

iCAD announced it is showcasing its ProFound AI Suite of clinically proven solutions for breast cancer detection, density assessment, and short-term risk evaluation in booth #228 at the AHRA 2023 annual meeting, taking place July 9-12 in Indianapolis, IN. “iCAD‘s Breast AI Suite is the only solution on the market today offering a complete portfolio of breast cancer detection, density assessment, and risk evaluation solutions that are clinically proven to increase cancer detection, assist radiologists in assessing short-term cancer risk, improve workflow, and enhance patient care. But when it comes to measuring impact, we don’t just stop at improving clinical outcomes. Our technology not only maximizes our customers’ clinical performance, it also boosts their bottom line,” said Dana Brown, President and CEO of iCAD, Inc.